OncoTherapy Science, Inc. (4564.T)
JPY 26.0
(-3.7%)
JPY 26.0
(-3.7%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 513.6 Million JPY | -21.74% |
| 2022 | 656.27 Million JPY | -6.91% |
| 2021 | 704.96 Million JPY | 142.02% |
| 2020 | 291.28 Million JPY | -19.0% |
| 2019 | 359.59 Million JPY | -27.63% |
| 2018 | 496.87 Million JPY | 12.49% |
| 2017 | 441.68 Million JPY | -9.58% |
| 2016 | 488.47 Million JPY | -10.94% |
| 2015 | 548.5 Million JPY | 0.67% |
| 2014 | 544.84 Million JPY | -31.58% |
| 2013 | 796.32 Million JPY | -32.84% |
| 2012 | 1.18 Billion JPY | -17.1% |
| 2011 | 1.43 Billion JPY | 53.05% |
| 2010 | 934.53 Million JPY | 12.68% |
| 2009 | 829.38 Million JPY | 104.23% |
| 2008 | 406.1 Million JPY | -34.15% |
| 2007 | 616.72 Million JPY | 147.89% |
| 2006 | 248.79 Million JPY | -31.95% |
| 2005 | 365.61 Million JPY | -51.13% |
| 2004 | 748.14 Million JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 547 Million JPY | 6.5% |
| 2023 Q3 | 275.03 Million JPY | 18.17% |
| 2023 FY | 513.6 Million JPY | -21.74% |
| 2023 Q4 | 513.6 Million JPY | 86.74% |
| 2023 Q2 | 232.73 Million JPY | -32.7% |
| 2023 Q1 | 345.8 Million JPY | -47.31% |
| 2022 Q1 | 373.24 Million JPY | -47.05% |
| 2022 Q2 | 339.69 Million JPY | -8.99% |
| 2022 Q3 | 391.99 Million JPY | 15.39% |
| 2022 FY | 656.27 Million JPY | -6.91% |
| 2022 Q4 | 656.27 Million JPY | 67.42% |
| 2021 Q3 | 490.96 Million JPY | -23.19% |
| 2021 Q4 | 704.96 Million JPY | 43.59% |
| 2021 Q2 | 639.22 Million JPY | 62.08% |
| 2021 FY | 704.96 Million JPY | 142.02% |
| 2021 Q1 | 394.39 Million JPY | 35.4% |
| 2020 Q4 | 291.28 Million JPY | 6.33% |
| 2020 FY | 291.28 Million JPY | -19.0% |
| 2020 Q1 | 259.43 Million JPY | -27.85% |
| 2020 Q3 | 273.93 Million JPY | 1.1% |
| 2020 Q2 | 270.95 Million JPY | 4.44% |
| 2019 Q3 | 397.66 Million JPY | -0.57% |
| 2019 Q2 | 399.95 Million JPY | 3.42% |
| 2019 Q4 | 359.59 Million JPY | -9.57% |
| 2019 FY | 359.59 Million JPY | -27.63% |
| 2019 Q1 | 386.72 Million JPY | -22.17% |
| 2018 Q1 | 357.82 Million JPY | -18.99% |
| 2018 Q4 | 496.87 Million JPY | 43.39% |
| 2018 Q3 | 346.52 Million JPY | -15.11% |
| 2018 FY | 496.87 Million JPY | 12.49% |
| 2018 Q2 | 408.2 Million JPY | 14.08% |
| 2017 Q2 | 376.35 Million JPY | -6.98% |
| 2017 FY | 441.68 Million JPY | -9.58% |
| 2017 Q1 | 404.6 Million JPY | -17.17% |
| 2017 Q3 | 510.6 Million JPY | 35.67% |
| 2017 Q4 | 441.68 Million JPY | -13.5% |
| 2016 Q4 | 488.47 Million JPY | -10.09% |
| 2016 FY | 488.47 Million JPY | -10.94% |
| 2016 Q3 | 543.27 Million JPY | 12.01% |
| 2016 Q2 | 485 Million JPY | -4.79% |
| 2016 Q1 | 509.42 Million JPY | -7.13% |
| 2015 Q4 | 548.5 Million JPY | -4.74% |
| 2015 Q2 | 554.91 Million JPY | -24.97% |
| 2015 Q1 | 739.6 Million JPY | 35.75% |
| 2015 FY | 548.5 Million JPY | 0.67% |
| 2015 Q3 | 575.77 Million JPY | 3.76% |
| 2014 Q4 | 544.84 Million JPY | -23.23% |
| 2014 FY | 544.84 Million JPY | -31.58% |
| 2014 Q3 | 709.67 Million JPY | 0.22% |
| 2014 Q2 | 708.08 Million JPY | 31.44% |
| 2014 Q1 | 538.69 Million JPY | -32.35% |
| 2013 Q3 | 915.84 Million JPY | -9.56% |
| 2013 Q4 | 796.32 Million JPY | -13.05% |
| 2013 Q2 | 1.01 Billion JPY | -10.73% |
| 2013 FY | 796.32 Million JPY | -32.84% |
| 2013 Q1 | 1.13 Billion JPY | -4.34% |
| 2012 FY | 1.18 Billion JPY | -17.1% |
| 2012 Q1 | 970.26 Million JPY | -32.17% |
| 2012 Q2 | 994.05 Million JPY | 2.45% |
| 2012 Q3 | 1.01 Billion JPY | 2.27% |
| 2012 Q4 | 1.18 Billion JPY | 16.63% |
| 2011 Q1 | 940.38 Million JPY | 0.63% |
| 2011 Q2 | 860.28 Million JPY | -8.52% |
| 2011 Q3 | 925.11 Million JPY | 7.54% |
| 2011 Q4 | 1.43 Billion JPY | 54.61% |
| 2011 FY | 1.43 Billion JPY | 53.05% |
| 2010 Q1 | 989.58 Million JPY | 19.32% |
| 2010 Q3 | 1.08 Billion JPY | -0.41% |
| 2010 Q4 | 934.53 Million JPY | -14.15% |
| 2010 FY | 934.53 Million JPY | 12.68% |
| 2010 Q2 | 1.09 Billion JPY | 10.46% |
| 2009 Q4 | 829.38 Million JPY | -9.57% |
| 2009 FY | 829.38 Million JPY | 104.23% |
| 2009 Q3 | 917.14 Million JPY | 0.0% |
| 2008 FY | 406.1 Million JPY | -34.15% |
| 2008 Q4 | 406.1 Million JPY | 0.0% |
| 2007 FY | 616.72 Million JPY | 147.89% |
| 2006 FY | 248.79 Million JPY | -31.95% |
| 2005 FY | 365.61 Million JPY | -51.13% |
| 2004 FY | 748.14 Million JPY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 3.24 Billion JPY | 84.182% |
| PRISM BioLab Co.,LTD | 63.41 Million JPY | -709.965% |
| GNI Group Ltd. | 26.34 Billion JPY | 98.05% |
| Linical Co., Ltd. | 10.3 Billion JPY | 95.016% |
| Trans Genic Inc. | 3.81 Billion JPY | 86.528% |
| MEDINET Co., Ltd. | 590.2 Million JPY | 12.978% |
| Soiken Holdings Inc. | 697.02 Million JPY | 26.314% |
| Cytori Cell Research Institute, Inc. | 3.02 Billion JPY | 82.997% |
| AnGes, Inc. | 2.78 Billion JPY | 81.587% |
| Nxera Pharma Co., Ltd. | 90.38 Billion JPY | 99.432% |
| Immuno-Biological Laboratories Co., Ltd. | 353.27 Million JPY | -45.386% |
| NanoCarrier Co., Ltd. | 1.64 Billion JPY | 68.87% |
| Carna Biosciences, Inc. | 472.35 Million JPY | -8.733% |
| CanBas Co., Ltd. | 91.98 Million JPY | -458.341% |
| D. Western Therapeutics Institute, Inc. | 1.09 Billion JPY | 53.035% |
| RaQualia Pharma Inc. | 809.83 Million JPY | 36.578% |
| Chiome Bioscience Inc. | 593.73 Million JPY | 13.495% |
| Kidswell Bio Corporation | 4.25 Billion JPY | 87.927% |
| PeptiDream Inc. | 29.11 Billion JPY | 98.236% |
| Oncolys BioPharma Inc. | 566.5 Million JPY | 9.337% |
| Ribomic Inc. | 155.8 Million JPY | -229.639% |
| SanBio Company Limited | 2.25 Billion JPY | 77.223% |
| Healios K.K. | 11.28 Billion JPY | 95.449% |
| BrightPath Biotherapeutics Co., Ltd. | 251.26 Million JPY | -104.405% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 369 Million JPY | -39.189% |
| Delta-Fly Pharma, Inc. | 241.49 Million JPY | -112.676% |
| StemRIM | 187 Million JPY | -174.656% |
| CellSource Co., Ltd. | 677.73 Million JPY | 24.218% |
| FunPep Company Limited | 189.32 Million JPY | -171.285% |
| Kringle Pharma, Inc. | 596.95 Million JPY | 13.962% |
| Stella Pharma Corporation | 1.44 Billion JPY | 64.422% |
| TMS Co., Ltd. | 97.68 Million JPY | -425.757% |
| Noile-Immune Biotech Inc. | 91.49 Million JPY | -461.356% |
| Cuorips Inc. | 200.96 Million JPY | -155.575% |
| K Pharma,Inc. | 209.13 Million JPY | -145.588% |
| Takara Bio Inc. | 11.42 Billion JPY | 95.503% |
| ReproCELL Incorporated | 741.03 Million JPY | 30.69% |
| PhoenixBio Co., Ltd. | 917.71 Million JPY | 44.034% |
| StemCell Institute Inc. | 3.85 Billion JPY | 86.661% |
| Japan Tissue Engineering Co., Ltd. | 908.43 Million JPY | 43.462% |
| CellSeed Inc. | 301.04 Million JPY | -70.607% |